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agnetic Resonance Imaging
nd Cardiac Pacemaker Safety at 1.5-Tesla
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ulsa, Oklahoma; Los Angeles, California; and Minneapolis, Minnesota
OBJECTIVES The study was done to determine whether patients with pacemakers could safely undergo
magnetic resonance imaging (MRI) at 1.5-Tesla (T).
BACKGROUND Because of theoretical risks, it is an absolute contraindication for a patient with a pacemaker
to undergo MRI. However, there are times when an MRI is needed to provide valuable
clinical information.
METHODS Fifty-four patients underwent a total of 62 MRI examinations at 1.5-T. The type of MRI
examination was not limited and included cardiac, vascular, and general MRI studies using
various whole-body averaged specific absorption rate (SAR) of radiofrequency power.
Restrictions were not placed on the type of pacemaker present in the patient. All pacemakers
were interrogated immediately before and after MRI scanning, and patients were continu-
ously monitored. Before and after MRI, interrogation was done, and pacing and sensing
thresholds, as well as lead impedances, were all measured.
RESULTS A total of 107 leads and 61 pulse generators were evaluated. No adverse events occurred. Forty
(37%) of the leads underwent changes, whereas 10 (9.4%) leads underwent a significant
change. Only 2 of the 107 (1.9%) leads required a change in programmed output. Threshold
changes were unrelated to cardiac chamber, anatomical location, peak SAR, and time from
lead implant to the MRI examination. Electrocardiographic changes and patient symptoms
were minor and did not require cessation of MRI.
CONCLUSIONS Safety was demonstrated in this series of patients with pacemakers at 1.5-T. (J Am Coll
Cardiol 2004;43:1315–24) © 2004 by the American College of Cardiology Foundationd
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iermanent cardiac pacemakers have represented a contra-
ndication to magnetic resonance imaging (MRI) (1,2).
trong static, gradient, and radiofrequency (RF) fields used
or MRI are thought to be detrimental to pacemaker
unction and possibly cause harm to patients undergoing
RI examinations. Potential adverse interactions between
acemakers and MRI include heating (3), induction of
See page 1325
entricular fibrillation (4), rapid atrial pacing (5), pacing at
ultiples of the RF pulse and associated rapid ventricular
acing (3,6–9), reed switch malfunction (6,10), asynchro-
ous pacing (6,7,9), inhibition of pacing output (3,5,6,11),
lteration of programming with potential damage to the
acemaker circuitry (5), or movement of the device (12–15).
otably, harmful effects to patients have also been docu-
ented. To date, 10 deaths have been attributed to MRI
rocedures in patients with pacemakers (16,17). However,
hese fatalities were poorly characterized, and no electrocar-
iographic (ECG) data were available (12). Importantly, no
From the *Oklahoma Heart Institute and †University of Oklahoma, Tulsa,
klahoma; ‡University of Southern California, Keck School of Medicine and
nstitute of Magnetic Resonance Safety, Education, and Research, Los Angeles,
alifornia; and §Integra CTS, Minneapolis, Minnesota.
Manuscript received September 4, 2003; revised manuscript received December 1,003, accepted December 3, 2003.eaths have been reported during physician-supervised MRI
rocedures (12).
Numerous patients with implanted pacemakers have
ndergone MRI either inadvertently or during purposeful,
onitored attempts to perform much needed examinations
11,18–26). These data suggest that MRI procedures are
ot as detrimental as once thought. Patients with pacemak-
rs have been successfully imaged using magnetic resonance
MR) systems operating at static field strengths ranging
rom 0.35-Tesla (T) to 1.5-T without any clinically adverse
vents (18–25). The investigators of these studies and
thers have also suggested certain strategies for performing
afe MRI procedures. These strategies included program-
ing the pacemaker device subthreshold (13,18,19,21) or to
synchronous mode (3,9,11,13,22,27), programming to a
ipolar lead configuration if possible (13,26), only imaging
on–pacemaker-dependent patients (13,25), limiting expo-
ure to RF power during MRI (9,13,19), and only perform-
ng MRI examinations if the pulse generator is positioned
utside of the bore of the MR system (20). Some have even
avored explanting the pulse generator prior to MRI (28).
Previous investigations have reported safety in dogs (29)
nd patients undergoing MRI procedures using MR sys-
ems operating at 1.5-T (10,11,19,20,23) and in a small
umber of patients at static magnetic field strengths at
.5-T (11,18,21,22). Of note is that a recent study has
dentified safe criteria for a neurostimulation system (which
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MRI and Pacemaker Safety April 7, 2004:1315–24s a pacing device for the brain with bilateral leads and dual
mplantable pulse generators) at 1.5-T (30).
Before the present investigation, no prospective study was
erformed in association with MR systems operating at
.5-T. Therefore, this prospective study of pacemaker
atients in need of MRI/magnetic resonance angiography
MRA) procedures was undertaken to establish a risk/
enefit profile that might broaden access to this important
iagnostic imaging modality.
ETHODS
tudy subjects. Between December 22, 1999, and Decem-
er 12, 2002, a total of 47 sequential patients with a
ermanent pacemaker and any clinical indication for MRI
rocedures were enrolled in a Hillcrest Medical Center
Tulsa, Oklahoma) Institutional Review Board-approved
rotocol and underwent 56 different MRI examinations at
he Oklahoma Heart Institute MRI Center. Patients were
ounseled regarding the risks of the MRI, and informed
onsent was obtained in all patients. A total of seven
acemaker patients had undergone seven medically neces-
ary MRI/MRA procedures, with informed consent, before
he development of the Institutional Review Board proto-
ol. Only pacemaker-dependent patients were excluded
rom this study, although one such patient inadvertently
nderwent MRI examination.
Data were obtained on all the patients, yielding a total of
4 sequential patients and 62 MRI/MRA examinations. An
xamination was considered separate if the patient exited
he MR system room after the study was completed. Repeat
xaminations were done on eight patients, with one patient
eceiving three separate examinations. No limitations were
laced on the type or duration of the MRI procedure,
acemaker, or lead models, nor proximity of the imaged
natomy relative to the pacemaker (Tables 1 and 2). All
RI/MRA studies were performed using an MR system
perating at a static magnetic field strength of 1.5-T (GE
igna CV/i, General Electric Medical Systems, Milwaukee,
isconsin). This MR system has high performance gradi-
nts with a slew rate of 150 T/m/s, a rise time of 268 s,
nd an amplitude of 40 mT/m.
re-MRI evaluation. An electrophysiologist interrogated
ach pacemaker. Data regarding initial programming, cap-
ure, and sensing thresholds, as well as lead impedances,
ere obtained. Rate histograms were cleared. Pacemakers
Abbreviations and Acronyms
ACLS  advanced cardiac life support
ECG  electrocardiographic/electrocardiography
MR  magnetic resonance
MRA  magnetic resonance angiography
MRI  magnetic resonance imaging
RF  radiofrequency
SAR  specific absorption rateere not programmed to the asynchronous mode or sub- shreshold. All patients were asked to report symptoms,
specially sensations of heat or movement, in the area of the
acemaker. Artifacts were noted on the MR images, when
resent.
atient monitoring. During MRI, continuous monitoring
as performed of the ECG signal and of symptoms through
oice contact with the patient via an intercom. Both an
lectrophysiologist and resuscitation equipment were avail-
ble during all MRI examinations.
ost-MRI evaluation. Symptoms and patient comments
ere recorded on a reporting form. Interrogations for
rogrammed parameters, capture and sensing thresholds,
ead impedances, battery voltage, and rate histograms were
erformed immediately upon exiting the MR system. Ap-
ropriate adjustments to the capture thresholds of the
acemakers were made when indicated.
tatistical analysis. All statistical analyses were conducted
ith SAS version 8.2 software (SAS Institute Inc., Cary,
orth Carolina). For each study subject, atrial and ventric-
lar pacing thresholds were measured before and after each
RI examination. Two primary outcomes were evaluated:
any change” and “any significant change” in pacing thresh-
ld after MRI. The outcomes were parameterized as binary
esponses (Yes/No), and changes were evaluated for an
ssociation with chamber (atrial vs. ventricular), anatomy
above or below diaphragm was used for ease of statistical
nalysis), peak RF power, specific absorption rate (SAR),
nd time from lead implant to MRI examination. Peak SAR
s a continuous variable, and its effect on pacing threshold
hange was evaluated in a logistic regression model. For all
ther analyses, a 22 contingency table is presented along
ith the corresponding p value. If an expected cell count for
ny 22 contingency table is 5, the reported p value is
rom Fisher exact test. Otherwise, reported p values are
rom the continuity-corrected chi-square test. In addition,
ultivariate logistic regression analysis was performed to
valuate each of the effects listed above in a pair-wise
ashion, and possible interactions were explored. The pri-
ary analyses treated the repeated measurements for those
ight patients with multiple MRI examinations, as well as
trial and ventricular leads in the same patient, as indepen-
ent observations. However, a repeated measures analysis
nder a logistic model using generalized estimating equa-
ions methodology was also conducted to account for any
ithin-patient correlation among repeated measurements.
ESULTS
fter the MRI examinations, no episodes of loss of capture
r changes in lead impedances or battery voltages were
oted. In addition, no damage to pacemaker circuits or
ovement of the pulse generator was observed.
atient symptoms. Patient symptoms were mild and in-
requent. Two patients had reported symptoms. One patient
elt his pacemaker vibrate during a coronary artery imaging
equence that used a spiral k-space acquisition, but this was
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April 7, 2004:1315–24 MRI and Pacemaker Safetyable 1. Pulse Sequences and Anatomical Imaging Locations for Patients Who Underwent MRI at 1.5-T
Patient
umber MRI Sequences Image Locations
1 T1 Spin Echo, T2, FSE, Fast GRE, 3D Vasc TOF SPGR MRA abdomen
2 T1 Spin Echo, Fast GRE, 3D Vasc TOF SPGR, GRE MRA neck
3 T1 Spin Echo, Fast GRE, 3D Vasc TOF SPGR MRA abdomen
4 T1 Spin Echo, Fast GRE, 3D Vasc TOF SPGR MRA neck
5 T1 Spin Echo, T2, FSE, FLAIR, T1 Spin Echo, T2, FSE w/Fat Sat MRI brain
6 T1 Spin Echo, GRE Cardiac
7 T1 Spin Echo, Fast GRE, 3D Vasc TOF SPGR MRA neck
8 T1 Spin Echo, GRE, Fast GRE, 3D Vasc TOF SPGR MRA neck
9 T1 Spin Echo, T2 Spin Echo Lumbar spine
10 T1 Spin Echo, T2 Spin Echo, FLAIR MRI brain
11 T1 Spin Echo, GRE, Fast GRE, 3D Vasc TOF SPGR MRA neck
12 T1 Spin Echo, T2 Spin Echo, FLAIR MRI brain
13 T1 Spin Echo, Fast GRE, 3D Vasc SPGR MRA lower extremities
14 T1 Spin Echo, SSFSE, Fast GRE, 3D Vasc TOF SPGR MRA abdomen
15 T1 Spin Echo, GRE, Fast GRE, 3D Vasc TOF SPGR MRA neck
16 T1 Spin Echo, SSFSE, Fast GRE, 3D Vasc TOF SPGR MRA neck
17 T1 Spin Echo, T2 Spin Echo, T2 Spin Echo w/Fat Sat Cervical spine
18 T1 Spin Echo, T2 Spin Echo MRI brain
19 T1 Spin Echo, T2 Spin Echo Lumbar spine
20 No sequences used—patient declined MRI but was exposed to static magnetic field MRA abdomen
21 T1 Spin Echo, SSFSE, Fast GRE, 3D Vasc TOF SPGR MRA abdomen
22 T1 Spin Echo, T2 Spin Echo, Flair, T1 Spin Echo w/Fat Sat MRI brain
23 T1 Spin Echo, GRE, Fast GRE, 3D Vasc TOF SPGR, Fast Cine PC, Fast Cine Tagged MRA neck, cardiac
24 T1 Spin Echo, Double IR, Fast Cine Tagged, Spiral Cardiac
25 T1 Spin Echo, T2 Spin Echo Lumbar spine
26 T1 Spin Echo, T2 Spin Echo, Flair, T1 Spin Echo w/Fat Sat MRI brain
27 T1 Spin Echo, T2 Spin Echo MRI abdomen, lumbar spine
28 T1 Spin Echo, SSFSE, GRE in and out of phase, T2 Spin Echo MRI abdomen
29 T1 Spin Echo, GRE MRI chest, shoulder
30 T1 Spin Echo, T2 Spin Echo, GRE MRI chest, shoulder
31 T1 Spin Echo, T2 Spin Echo, Flair, 3D Vasc TOF, T1 Spin Echo w/Fat Sat MRI brain
32 T1 Spin Echo, Fast GRE, 3D Vasc TOF SPGR MRA neck
33 T1 Spin Echo, T2 Spin Echo, T2 Spin Echo w/Fat Sat Cervical spine
34 T1 Spin Echo, T2 Spin Echo, 3D Vasc TOF, GRE, 2D Vasc TOF, Fast GRE MRI brain, MRA neck
35 T1 Spin Echo, T2 Spin Echo MRI chest, brachial plexus
36 T1 Spin Echo, GRE, 2D Vasc TOF, Fast Cine PC, Fast GRE, 3D Vasc TOF SPGR MRA neck
37 T1 Spin Echo, GRE, 2D Vasc TOF, Fast GRE, STIR, 3D Vasc TOF MRA neck
38 T1 Spin Echo, GRE, SSFP, Fast Cine Tagged Cardiac
39 GRE, 3D Vasc TOF SPGR MRA lower extremities
40 T1 Spin Echo, T2 SSFSE, GRE, 3D Vasc TOF SPGR MRA abdomen
41 3D Vasc TOF SPGR, GRE MRA abdomen and lower extremities
42 T1 Spin Echo, T2 Spin Echo, Flair MRI brain
43 3D Vasc TOF SPGR MRA abdomen and lower extremities
44 Spin Echo, T2 SSFSE, Fast GRE, 3D Vasc TOF SPGR MRA abdomen
45 T1 Spin Echo, T2 Spin Echo, STIR, GRE, 3D Vasc TOF SPGR Pelvic MRI and MRA
46 T1 Spin Echo, T2 Fast Spin Lumbar spine
47 T1 Spin Echo, FSE w/Fat Sat, 2D Vasc TOF SPGR, Fast Cine PC, Fast GRE Cervical spine, MRA neck
48 T1 Spin Echo, T2 Spin Echo, Fat Sat, T1 Fat Sat MRI brain
49 T1 Spin Echo, T2 FSE, 3D Vasc TOF SPGR MRA brain
50 T1 Spin Echo, T2 Fast Spin Lumbar spine
51 T1 Spin Echo, T2 FSE, T2 FSE w/Fat Sat Lumbar spine, cervical spine
52 T1 Spin Echo, T2 FSE Cervical spine
53 T1 Spin Echo Lumbosacral spine
54 T1 Spin Echo, GRE, 3D Vasc TOF SPGR MRA lower extremities
55 Spin Echo, T1 FSE, T2 FSE Lumbar spine
56 T1 Spin Echo, T2 Spin Echo Lumbar spine
57 T1 FSE, T2 FSE, T1 Spin Echo, FLAIR MRI brain
58 T1 Spin Echo, T1 FSE, T2 FSE MRI brain, cervical spine
59 No MRI—pacemaker dependent No MRI-pacer dependent
60 T1 Spin Echo, T1 FSE, T2 FSE, FLAIR MRI brain
61 T1 Spin Echo, T2 FSE Cervical spine
62 T1 Spin Echo, 3D Vasc TOF SPGR, Double IR FSE MRA abdomen and lower extremities
63 T1 Spin Echo, T2, FSE, FLAIR MRI brain
at Sat  fat saturation; FLAIR  fluid attenuated inversion recovery; FSE  fast spin echo; GRE  gradient-recalled echo; IR  inversion recovery; MRA  magnetic
esonance angiography; MRImagnetic resonance imaging; PC phase contrast; SPGR spoiled gradient recalled echo; SSFP steady state free precession; SSFSE single
hot fast spin echo; STIR  Short TI inversion recovery; TOF  time-of-flight; Vasc  vascular.
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MRI and Pacemaker Safety April 7, 2004:1315–24able 2. Pre- and Post-MRI Thresholds, Lead Information, Pacemaker Model, Highest Specific Absorption Rate, and Granularity
nformation for Patients With Pacemakers Who Underwent MRI at 1.5-T
Patient
umber
Pacer
Model
Highest SAR
(W/kg) Pre-MRI Post-MRI
Year of
Lead Implant
1 PSE 2022 2.0 A 2.0 v @ 0.6 ms 1.5 v @ 0.6 ms 1996
V 3.0 v @ 0.6 ms 3.0 v @ 0.6 ms 1996
2 MDT 7088 1.73 A 2.5 v @ 0.06 ms 2.5 v @ 0.09 ms 1999
V 2.5 v @ 0.09 ms 2.5 v @ 0.09 ms 1999
3 PSE 2028 1.95 A 1 v @ 0.6 ms 2.0 v @ 0.6 ms 1995
V 2.0 v @ 0.6 ms 1.5 v @ 0.6 ms 1995
4 MDT 8161 1.67 A N/A N/A N/A
V 2.5 v @ 0.06 ms 2.5 v @ 0.06 ms 1987
5 GDT 940 0.08 A 2.5 v @ 0.1 ms 2.5 v @ 0.1 ms 1994
V 2.5 v @ 0.2 ms 2.5 v @ 0.2 ms 1994
6 INT 281-055 0.81 A PPM at end of life PPM at end of life 1999
V At time of MRI At time of MRI 1999
7 MDT 7960 1.65 A 2.5 v @ 0.2 ms 2.5 v @ 0.2 ms 1998
V 2.5 v @ 0.03 ms 2.5 v @ 0.03 ms 1998
8 MDT 7074 1.65 A 2.5 v @ 0.12 ms 2.5 v @ 0.12 ms 1992
V  2.5 v @ 0.03 ms  2.5 v @ 0.03 ms 1992
9 MDT 7088 1.99 A 1.5 v @ 0.5 ms 1.5 v @ 0.5 ms 1997
V 1.0 v @ 0.5 ms 1.0 v @ 0.5 ms 1993
10 MDT 1226 0.08 A 2.5 v @ 0.24 ms 2.5 v @ 0.24 ms 1994
V 2.5 v @ 0.06 ms 2.5 v @ 0.06 ms 1994
11 GDT 1230 1.55 A 1.6 v @ 0.5 ms 1.6 v @ 0.5 ms 1997
V 1.6 v @ 0.5 ms 1.6 v @ 0.5 ms 1997
12 GDT 940 0.08 A 2.5 v 0.2 ms 2.5 v @ 0.3 ms 1994
V 2.5 v @ 0.2 ms 2.5 v @ 0.2 ms 1994
13 MDT 7088 1.72 A 1.0 v @ 0.4 ms 1.0 v @ 0.4 ms 1997
V 1.0 v @ 0.4 ms 1.0 v @ 0.4 ms 1997
14 MDT 7088 2.0 A 2.5 v @ 0.06 ms 2.5 v @ 0.09 ms 1998
V 2.5 v @ 0.09 ms 2.5 v @ 0.09 ms 1998
15 PSE 2022 1.84 A 1.5 v @ 0.4 ms 1.5 v @ 0.4 ms 1992
V 1.5 v @ 0.6 ms 1.5 v @ 0.6 ms 1992
16 GDT 1230 2.0 A 1.4 v @ 0.4 ms 1.9 v @ 0.4 ms 1996
V 1.1 v @ 0.4 ms 1.2 v @ 0.4 ms 1996
17 INT 291-03 1.43 A N/A N/A N/A
V 2.0 v @ 0.2 ms 2.5 v @ 0.2 ms 1986
18 GDT 1170 0.08 A 0.6 v @ 0.4 ms 0.6 v @ 0.4 ms 1999
V N/A N/A N/A
19 GDT 1274 2.0 A 0.9 v @ 0.4 ms 0.9 v @ 0.4 ms 1998
V 1.1 v @ 0.4 ms 1.1 v @ 0.4 ms 1998
20 MDT KDR 401 N/A A 2.5 v @ 0.09 ms 2.5 v @ 0.09 ms 1998
V 2.5 v @ 0.06 ms 2.5 v @ 0.06 ms 1998
21 INT 294-0 2.0 A 3.5 v @ 0.15 ms 3.5 v @ 0.15 ms 1999
V 3.0 v @ 0.1 ms 3.0 v @ 0.1 ms 1999
22 MDT 8416 0.08 A N/A N/A N/A
V 2.5 v @ 0.15 ms 2.5 v @ 0.15 ms No data
23 PSE 2016 1.71 A 0.5 v @ 0.4 ms 1.0 v @ 0.4 1993
V 0.5 v @ 0.4 ms 1.5 v @ 0.4 ms 1993
24 PSE 2022 1.21 A 1.0 v @ 0.4 ms 1.5 v @ 0.4 ms 1995
V N/A N/A 1995
25 MDT 8088 1.97 A N/A N/A N/A
V 3.0 v @ 0.12 ms 3.0 v @ 0.12 ms 1997
26 GDT 1274 0.08 A 1.4 v @ 0.4 ms 1.0 v @ 0.4 ms 1998
V 0.8 v @ 0.4 ms 0.9 v @ 0.4 ms 1998
27 GDT 1232 1.98 A 1.3 v @ 0.4 ms 1.3 v @ 0.4 ms 1997
V 1 v @ 0.5 ms 1.2 v @ 0.4 ms 1997
28 GDT 1286 2.0 A 0.6 v @ 0.4 ms 0.6 v @ 0.4 ms 2000
V 1.0 v @ 0.4 ms 1.0 v @ 0.4 ms 2000
29 MDT SDR 303 1.61 A 2.5 v @ 0.03 ms 2.5 v @ 0.03 ms 2000
V 1.5 v @ 0.3 ms 1.5 v @ 0.3 ms 2000
30 MDT SDR 303 1.61 A 2.5 v @ 0.06 ms 2.5 v @ 0.06 ms 2000
V 2.5 v @ 0.12 ms 2.5 v @ 0.12 ms 2000
31 GDT 1274 0.08 A 0.9 v @ 0.4 ms 1.0 v @ 0.4 ms 1999
V 0.8 v @ 0.4 ms 0.8 v @ 0.4 ms 1999
Continued on next page
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Patient
umber
Pacer
Model
Highest SAR
(W/kg) Pre-MRI Post-MRI
Year of
Lead Implant
32 GDT 1176 1.97 A N/A N/A N/A
V 1.3 v @ 0.5 ms 1.3 v @ 0.5 ms 1993
33 PSE 2350 1.78 A 2.5 v @ 0.6 ms 2.5 v @ 0.6 ms 1996
V 1.5 v @ 0.6 ms 1.5 v @ 0.6 ms 1993
34 MDT 7074 1.98 A 1.6 v @ 0.18 ms 1.6 v @ 0.18 ms 1992
V 2.5 v @ 0.12 ms 2.5 v @ 0.12 ms 1992
35 PSE 2350 1.56 A 2.5 v @ 0.6 ms 2.5 v @ 0.6 ms 1996
V 1.5 v @ 0.6 ms 1.5 v @ 0.6 ms 1993
36 MDT KDR 401 1.98 A 0.5 v @ 0.4 ms 0.5 v @ 0.4 ms 2001
V 1.0 v @ 0.4 ms 0.5 v @ 0.4 ms 2001
37 PSE 2364 1.98 A 1.0 v @ 0.6 ms 1.0 v @ 0.6 ms 1997
V 2.5 v @ 0.6 ms 2.5 v @ 0.6 ms 1997
38 GDT 1276 1.69 A 1.1 v @ 0.4 ms 1.5 v @ 0.4 ms 1999
V 0.9 v @ 0.4 ms 1.1 v @ 0.4 ms 1999
39 GDT 1270 1.98 A N/A N/A N/A
V 0.6 v @ 0.4 ms 0.7 v @ 0.4 ms 2000
40 GDT 1270 1.98 A 1.2 v @ 0.4 ms 1.2 v @ 0.4 ms 2000
V 0.8 v @ 0.4 ms 0.8 v @ 0.4 ms 2000
41 MDT KDR 401 1.97 A 2.5 v @ 0.06 ms 2.5 v @ 0.06 ms 1999
V 2.5 v @ 0.09 ms 2.5 v @ 0.09 ms 1999
42 GDT 1270 1.81 A 1.1 v @ 0.4 ms 1.1 v @ 0.4 ms 2001
V 1.0 v @ 0.4 ms 1.1 v @ 0.4 ms 2001
43 GDT 1176 1.97 A N/A N/A N/A
V 1.0 v @ 0.4 ms 1.1 v @ 0.4 ms 1993
44 GDT 1270 2.00 A N/A N/A 2001
V 0.8 v @ 0.4 ms 1.1 v @ 0.4 ms 2001
45 GDT 1270 1.58 A 0.6 v @ 0.4 ms 0.7 v @ 0.4 ms 2000
V 1.1 v @ 0.4 ms 1.1 v @ 0.4 ms 2000
46 GDT 1270 1.66 A 1.1 v @ 0.4 ms 1.3 v @ 0.4 ms 2001
V 1.1 v @ 0.4 ms 1.0 v @ 0.4 ms 2001
47 GDT 1270 1.70 A 1.1 v @ 0.4 ms 1.4 v @ 0.4 ms 2001
V 1.1 v @ 0.4 ms 1.3 v @ 0.4 ms 2001
48 MDT KDR 721 0.08 A Afib N/A 2001
V 1.5 v @ 0.76 ms 1.25 v @ 0.76 ms 2001
49 GDT 1270 0.06 A 0.6 v @ 0.4 ms 0.7 v @ 0.4 ms 2000
V 1.1 v @ 0.4 ms 1.1 v @ 0.4 ms 2000
50 MDT 7074 1.67 A N/A N/A 1991
V 2.5 v @ 0.12 ms 2.5 v @ 0.12 ms 1991
51 MDT SDR 303 1.93 A 3.0 v @ 0.12 ms 3.0 v @ 0.12 ms 2000
V 2.5 v @ 0.06 ms 2.5 v @ 0.06 ms 2000
52 GDT 1280 1.84 A 0.8 v @ 0.4 ms 0.9 v @ 0.4 ms 2001
V 1.2 v @ 0.4 ms 1.3 v @ 0.4 ms 2001
53 INT 294-03 1.82 A 3.5 v @ 0.2 ms 3.5 v @ 0.2 ms 1993
V 1.5 v @ 0.45 ms 1.5 v @ 0.45 ms 1993
54 MDT SDR 303 0.85 A 2.5 v @ 0.06 ms 2.5 v @ 0.06 ms 2002
V 7.5 v @ 0.2 ms 7.5 v @ 0.2 ms 2002
55 GDT 1280 1.76 A 1.0 v @ 0.4 ms 1.0 v @ 0.4 ms 2001
V 1.3 v @ 0.5 ms 1.5 v @ 0.5 ms 2001
56 GDT 1270 1.58 A 0.8 v @ 0.4 ms 0.9 v @ 0.4 ms 2000
V 0.7 v @ 0.4 ms 0.7 v @ 0.4 ms 2000
57 GDT 1270 0.08 A 0.9 v @ 0.4 ms 0.9 v @ 0.4 ms 1994
V 1.5 v @ 0.4 ms 1.6 v @ 0.4 ms 1994
58 GDT 1270 1.85 A N/A N/A 2000
V 0.7 v @ 0.4 ms 0.8 v @ 0.4 ms 2000
59 MDT DR 7088 N/A A 2.5 v @ 0.6 ms No MRI—pacemaker-dependent patient 1998
V 2.5 v @ 0.35 ms 1998
60 GDT 1180 0.08 A N/A N/A N/A
V 1.0 v @ 0.4 ms 1.1 v @ 0.4 ms 2002
61 GDT 1272 1.72 A 0.6 v @ 0.4 ms 0.7 v @ 0.4 ms 1998
V 0.8 v @ 0.4 ms 0.7 v @ 0.4 ms 1998
62 MDT 8160 1.42 A N/A N/A N/A
V 2.5 v @ 0.09 ms 2.5 v @ 0.09 ms 1993
63 GDT 1276 0.08 A 0.9 v @ 0.4 ms 1.1 v @ 0.4 ms 1998
V 1.4 v @ 0.5 ms 1.2 v @ 0.5 ms 1998
 atrium; GDTGuidant; INT Intermedics; MDTMedtronic; MRImagnetic resonance imaging; PSE Pacesetter; SAR specific absorption rate; V ventricle.
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MRI and Pacemaker Safety April 7, 2004:1315–24ransient. Another patient felt palpitations during a time of
acemaker inhibition. No MRI procedures were terminated
s a result of any of the observed symptoms. Pacemakers
lso did not interfere with the interpretation of the MR
mages.
hreshold changes. Of the 62 examinations, only 61 were
valuated, because one pacemaker was at the end-of-life.
his yielded data on 107 leads, of which 48 were atrial and
9 were ventricular. Each lead was evaluated for “any
hange” in pacing threshold and “any significant change.” A
ignificant change was defined as a change 1 voltage or
ulse width increment or decrement, because changes
maller than that can be encountered frequently by chance.
Pacing thresholds changed in 40 of 107 (37%) leads. Of
he 40 leads that changed, only 10 (9.4%) leads were judged
o be a significant change. Only 2 of the 107 (1.9%) leads
equired a change in programmed output.
Changes were evaluated for an association with cardiac
hamber, anatomy, peak SAR, and time from pacemaker
ead implant to MRI examination. With regard to cardiac
hamber analysis, 19 of the 48 atrial pacing thresholds
39.5%) changed after MRI, and 6 of these were significant
12.5%). Similarly, 21 of the 59 ventricular pacing thresh-
lds changed after MRI (35.6%), 4 of which were signifi-
ant (6.8%). There was no association between changes in
acing thresholds and cardiac chamber, with chi-square p
alues of 0.82 and 0.50 for “any change” and “any significant
hange,” respectively (Tables 3 and 4). A repeated measures
nalysis was also conducted to account for the within-
atient correlation between changes in ventricular and atrial
acing thresholds. This analysis demonstrated indepen-
ence of atrial and ventricular pacing threshold changes
ithin a patient (p  0.6 for “any change” and p  0.2 for
any significant change”). Therefore, all further analyses
ere conducted using each lead as the unit for analysis, and
he atrial and ventricular leads were combined.
For statistical analysis, the imaged anatomical location
able 3. Any Pacemaker Threshold Changes by Cardiac
hamber
hamber
Any Change
No Yes Total
trium 29 19 48
entricle 38 21 59
otal 67 40 107
wo-sided continuity corrected chi-square, p value  0.82.
able 4. Significant Pacemaker Threshold Changes by Cardiac
hamber
hamber
Significant Change
No Yes Total
trium 42 6 48
entricle 55 4 59
otal 97 10 107Two-sided continuity corrected chi-square, p value  0.50.as defined and grouped as above or below the diaphragm.
ne patient with both an atrial and ventricular lead had an
RI procedure both above and below the diaphragm
uring the same examination and, therefore, was excluded
rom the analysis. Twenty-six of 61 (42.6%) pacing thresh-
lds changed after an MRI above the diaphragm, and 7
11.5%) of these were significant. Fourteen of 44 (31.8%)
acing thresholds changed after an MRI below the dia-
hragm, 3 (6.8%) of which were significant. The chi-square
values associated with anatomy are 0.36 for “any change”
n pacing threshold and 0.64 for “any significant change.”
herefore, no association existed between changes in pacing
hreshold and region of anatomy that underwent imaging
Tables 5 and 6).
The log-odds ratio of any change in pacing threshold
ersus peak SAR was 0.41, with a corresponding p value of
.14. As SAR increases by one unit, the odds of experienc-
ng any change in pacing threshold increase 50%. However,
he odds of a significant change in pacing threshold decrease
s SAR increases (log-odds  0.17; p  0.74). Because
he outcome is not statistically significant and the log-odds
atios are relatively close to 1, the disparate directional
ssociation is likely due to random variation.
Time from lead implant to the MRI examination was
hen examined to see whether this factor was related to
hreshold changes. Although over 40% of recent implants (0
o 4 years prior to MRI examination) experienced a change
n pacing thresholds compared with approximately 20% for
lder leads, the comparison across implant times was not
tatistically significant for “any change” in pacing thresholds
p  0.11; Fisher exact test) or for “any significant change”
n thresholds (p  0.63; Fisher exact test) (Tables 7 and 8).
Results of the multivariate logistic regression analyses
emonstrated no interactive effects, with p values for the
nteraction tests ranging from 0.37 (anatomical location by
AR) to 0.64 (anatomical location by chamber). Effects of
ach predictor in the multivariate analyses were consistent
ith that predictor’s effect in the multivariate model.
able 6. Significant Pacemaker Threshold Changes by Anatomy
maged
natomy
Significant Change
No Yes Total
bove 54 7 61
elow 41 3 44
otal 95 10 105
able 5. Any Pacemaker Threshold Changes by Anatomy
maged
natomy
Any Change
No Yes Total
bove 35 26 61
elow 30 14 44
otal 65 40 105
wo-sided continuity corrected chi-square, p value  0.36.wo-sided continuity corrected chi-square, p value  0.64.
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April 7, 2004:1315–24 MRI and Pacemaker SafetyCG changes. Additionally, changes were seen on the
CG during testing that were clinically without symptoms
r consequence. Atrial over-sensing of electromagnetic
oise leading to ventricular tracking at the upper rate limit
f the pacemaker was seen in two patients. Another episode
f atrial over-sensing led to inhibition of pacing in an AAI
ystem. Ventricular over-sensing with pacing inhibition for
ne heart beat occurred in one patient. Five patients
xhibited transient non–magnet-mode behavior, most likely
ue to an open reed switch. Finally, one pacemaker with a
inute ventilation feature sensed noise as an increase in
inute ventilation and, therefore, paced at the upper rate
imit. All other devices demonstrated magnet-mode behav-
or during the MRI procedure. No episodes of pacing above
he upper rate limit were noted, and no arrhythmias were
ncountered.
ISCUSSION
agnetic resonance imaging has become the ideal test in
any areas of clinical medicine. Because of its high spatial
nd contrast resolution, it is now the primary diagnostic
maging test of choice for disorders of the central nervous
nd musculoskeletal systems. It is also important for onco-
ogical and certain cardiovascular disorders. In certain clin-
cal instances, denying a patient an MRI procedure may
ave a significant effect on the patient’s care. Subsequently,
his could prove to have a major impact on overall public
ealth. The most recent data from 2002 suggest that 2.4
illion people in the U.S. now have permanent implanted
acemakers. An additional 430,000 individuals are esti-
ated to undergo pacemaker implantation in 2003 (Scot
ilchman, Guidant Corporation, St. Paul, Minnesota,
ersonal communication, April 28, 2003). This large group
f patients is presently being denied a potentially important
iagnostic examination.
In 1999, a Japanese study polled 1,567 pacemaker pa-
able 7. Any Change in Pacemaker Thresholds by Time
etween Pacemaker Lead Implant and MRI Examination
ears Yes No. Total
–2 24 (42%) 33 57
–4 9 (47%) 10 19
–6 2 (20%) 8 10
6 5 (25%) 15 20
otal 40 (38%) 66 106
wo-sided Fisher exact test, p value  0.11.
able 8. Significant Changes in Pacemaker Thresholds by Time
etween Pacemaker Lead Implant and MRI Examination
ears Yes No Total
–2 5 (9%) 52 57
–4 2 (11%) 17 19
–6 0 (0%) 10 10
6 3 (15%) 17 20
otal 10 (9%) 96 106mwo-sided Fisher exact test, p value  0.63.ients and reported that 17% needed MRI procedures
uring the previous year but were denied because of the
resence of an implanted cardiac pacemaker (31). Applying
his percentage to the current number of people in the U.S.
ith pacemakers yields 408,000 individuals. This is a major
ublic health issue, as these patients may have to undergo an
nferior imaging procedure or an invasive examination,
eading to a possible missed diagnosis and/or increased
orbidity.
indings from the present study. In the current study, to
xamine risk in the broadest possible population, no restric-
ions were placed on the anatomy that underwent imaging,
he type of pulse sequence, or the conditions used for MRI,
or on the type of pacemaker present in the patient. Only
acemaker-dependent patients were excluded (with the
xception of one patient who inadvertently underwent
RI) so as to eliminate problems if pacing was inhibited
uring the MRI procedure. Furthermore, the decision was
ade not to program to an asynchronous mode because
acemakers automatically enter the asynchronous mode
hen in the presence of a powerful static magnetic field.
acemakers were also not programmed to subthreshold
ecause it was believed that the risk of developing ventric-
lar fibrillation during asynchronous pacing was extremely
ow. This assumption is supported by the fact that numerous
imes transtelephonic pacemaker interrogations occur with-
ut incident on a daily basis. However, resuscitation equip-
ent and advanced cardiac life support (ACLS)-trained
ersonnel were readily available if problems arose for those
atients in the MR environment.
hreshold changes. The threshold data were analyzed
ith respect to SAR, anatomy imaged, cardiac chamber,
nd time from lead implant to the MRI examination. Any
hange in threshold was considered important, even though
nly increases in these values are detrimental.
One study suggests that limiting the distance from the
acemaker pulse generator to the anatomical region being
maged is beneficial to MRI safety (20). Therefore, the data
ere analyzed with respect to the anatomy that underwent
maging. For ease of statistical analysis, the MRI examina-
ions were grouped into above and below the diaphragm.
either anatomical region was associated with pacing
hreshold changes.
Pacing thresholds were also examined as a function of
ardiac chamber. It was theorized that the atrium, because
f its smaller mass with possible less heat transfer, would
ore readily undergo threshold changes than would the
entricle. However, the atrium was no more likely to
evelop pacing threshold changes than was the ventricle.
Because the level of the SAR (i.e., the dosimetric term
sed to indicate the amount of RF energy used during an
RI procedure) has been shown to be responsible for the
elative amount of heating that occurs for medical implants,
ncluding pacemakers and neurostimulation systems
2,3,31,32), it was believed that the higher the SAR the
ore likely the pacemaker lead would be to heat and cause
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MRI and Pacemaker Safety April 7, 2004:1315–24ubsequent threshold changes. However, there were no
ndings to support this suspicion. Threshold changes were
nrelated to the peak whole-body–averaged SARs associ-
ted with the MRI procedures for the patients in the present
tudy.
We theorize that pacing threshold changes may occur
ecause of electrode heating. Pacing leads have been shown
o heat in vitro to 88.8°C (3). This is well above ablation
emperature, and if it occurred in vivo the pacemaker device
ould no longer be able to pace the myocardium. Therefore,
ome intrinsic heat transfer must be occurring and is most
ikely due to flowing blood and myocardial mass. We
ostulate that the declines of threshold represent mild levels
f heating at the lead-tissue interface, whereas temperature
ises are secondary to higher levels of thermal injury. Proof
f this theory is absent but is supported by observations that
irror these changes in the electrophysiology laboratory.
espite the pacing threshold changes observed in the
resent study, no serious adverse events were observed
espite the use of the 1.5-T MR system and the lack of
xclusions for MRI techniques and body parts that under-
ent examinations.
The significant pacing threshold changes noted during
ur study were infrequent and all easily addressed with
ubtle programming changes. The energy increases that
ere needed to accommodate the rise in thresholds were
inor and did not impair the safe performance of the pulse
enerators. Despite the labeling of these changes as signif-
cant, they were of no clinical consequence. Changes of
hese magnitudes are commonly observed in the daily
ractice of cardiology.
CG changes. Finally, minor ECG changes were encoun-
ered, and these were varied and transient as described
reviously. Pacing inhibition was seen briefly in one atrial
nd one ventricular lead. It was because of this potential
roblem with inhibition, especially in the ventricular leads,
hat we chose not to include pacemaker-dependent patients
n the study. The pacemaker inhibition phenomenon has
een reported previously (5,11). Depending on the length of
ime of the inhibition, there could be a prolonged period of
systole. For this reason or because of induction of ventric-
lar fibrillation, we postulate that some pacemaker patients
ave previously died in association with an MRI procedure
16,17). Non–magnet-mode response occurred in five pa-
ients, suggesting that the reed switch can open and close
uring MRI. This is consistent with previous reports
14,33) and was not an issue clinically.
A minute-ventilation pacemaker sensed noise as an in-
rease in minute ventilation and paced at the upper rate
imit. This patient happened to undergo two MRI exami-
ations, and during the second examination the minute-
entilation feature was disabled and no upper rate limit
acing was seen.
All of the above noted instances were brief, and none was
ssociated with clinical consequences. Finally, electromag-
etically induced noise was encountered occasionally on aelemetry. This was monitored closely, because it can
esemble serious cardiac arrhythmias.
atient symptoms. Patient symptoms were mild and tran-
ient. One patient reported vibration, but this could not be
isually confirmed. Vibration of a device in association with
n MRI procedure has been previously reported (34). One
ther patient had palpitations. This coincided with the
nhibition of pacing in the ventricular lead. None of these
ymptoms required cessation of MRI. The presence of the
acemakers also did not affect the operation of the MR
ystem or the interpretation of the MR images.
ther electronically activated devices. In the past, the
resence of an electronically activated implant was consid-
red a strict contraindication for a patient or individual in
he MR environment (2). However, over the years, various
tudies have been performed to define safety criteria for
lectronic devices including pacemakers, implantable car-
ioverter defibrillators, neurostimulation systems, cochlear
mplants, a drug infusion pump, and a bone fusion stimu-
ator (19,20,31,32,34–43). As such, findings have indicated
hat, if highly specific guidelines are followed, MRI proce-
ures may be conducted safely in patients with electronically
ctivated implants (19,20,31,32,34–49). Notably, some of
hese electronically activated devices have received approval
f “MR safe” labeling claims from the U.S. Food and Drug
dministration. Accordingly, it is hoped that cardiac pace-
aker manufacturers will be encouraged by the results of
he present study to pro-actively support and/or conduct
nvestigations directed toward identifying MRI safety crite-
ia for their respective devices. This will ultimately have a
ubstantial impact on patient management and the overall
ealth care of pacemaker patients who might require MRI
rocedures.
Given the infinite possibilities of pacing systems and
ardiac and lead geometry, as well as variable static, gradi-
nt, and RF electromagnetic fields and conditions used for
RI procedures, the absolute safety of pacemaker and MRI
nteractions presently cannot be assured. However, given
ppropriate patient selection as well as continuous monitor-
ng and preparedness for resuscitation efforts with ACLS-
rained personnel in attendance, performance of MRI pro-
edures on non–pacemaker-dependent patients may be
chieved with reasonable safety, even at static magnetic field
trengths of 1.5-T with an acceptable risk/benefit profile.
Finally, it should be noted that the findings described
erein are highly specific to the MR system, the software
ersion running the scanner, MRI conditions, and types of
acemakers and lead systems present in the patients. Other
actors that potentially impact MRI safety for patients with
acemakers will need to be defined.
ecommendations. Given the results of the current study,
he following guidelines should be followed to reduce the
hance of an adverse pacemaker/MRI interaction: 1) obtain
nformed consent; the patient needs to understand that
here is still a potential risk; 2) have emergency equipment
nd ACLS-trained personnel readily available; 3) interro-
g
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April 7, 2004:1315–24 MRI and Pacemaker Safetyate the pulse generator immediately before and after MRI;
) disable the minute ventilation feature; 5) maintain voice
ontact throughout the procedure and continuously monitor
eart rhythm and rate; 6) because subtle pacemaker pro-
ramming changes occasionally are needed, a physician
acile in the ways of pacemaker programming needs to be
vailable; and 7) with respect to subthreshold output pro-
ramming, previous investigators have suggested this ap-
roach to minimize induction of ventricular fibrillation.
his approach is reasonable but may not be necessary when
he aforementioned guidelines are followed.
ossible study limitations. A possible limitation of this
tudy is that the effects of MRI-related heating were not
irectly measured. Also, no comment could be made re-
arding pacemaker-dependent patients, as they were inten-
ionally not included in the study population.
ONCLUSIONS
n this series of 62 non–pacemaker-dependent patient
xaminations, performance of unrestricted MRI procedures
sing a 1.5-T MR system was found to have an acceptable
afety profile. Patient symptoms were mild and transient
nd did not lead to discontinuation of the examinations.
ignificant alteration of the pacing threshold was found in a
mall number of leads tested. These threshold changes
equired a programmed output change in only two leads and
ere of no clinical consequence. The threshold changes
ere unrelated to cardiac chamber, anatomical location, and
ime from lead implant to MRI examination and highest
hole body SAR. Therefore, the belief in the presence of a
acemaker as an absolute contraindication to MRI should
e re-evaluated.
eprint requests and correspondence: Dr. Edward T. Martin,
klahoma Heart Institute, 9228 South Mingo Road, Tulsa,
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